Y's Therapeutics Completes Study Patient Enrollment
Posted on: Tuesday, 24 April 2007, 12:01 CDT
Japanese biopharmaceutical company Y's Therapeutics has completed patient enrollment for its phase II clinical trial of its compound YSPSL for prevention of delayed graft function (DGF) in kidney transplant patients.
The underlying cause of DGF is injury when blood re-flows into ischemic tissue, in this case the newly transplanted organ, causing inflammation and subsequent tissue damage.
The clinical trial enrolled 75 patients across 15 leading US transplant centers to evaluate the safety and efficacy of YSPSL (r-PSGL-Ig, recombinant P-selectin glycoprotein immunoglobulin) for prevention of DGF in patients undergoing cadaveric kidney transplantation.
Masanori Murayama, representative director of Y's Therapeutics, said: "The success of YSPSL in a variety of animal models, including recent data in percutaneous cardiac intervention, makes it an attractive investigational agent for development in other indications."
The results from the phase II clinical trial, including the placebo-controlled, blinded portion of the study, will be available after analysis of the six-month follow-up data of all enrolled patients in the study.
Source: Datamonitor
Related Articles
- Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
- HeartWare International Clinical Trial Shows 90% Survival at 180 Days
- Stratatech Successfully Completes Clinical Trial of StrataGraft(R) Skin Substitute
- Cytokinetics Announces Interim Clinical Trial Data Relating to Ispinesib Presented at the 2008 ASCO Breast Cancer Symposium
- Cytokinetics Announces the Initiation of a Phase I/II Clinical Trial for Ispinesib in Metastatic Breast Cancer
- Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane As Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
- Clinical Trial to Begin for Stem Cell Treatment in Heart Patients
- ZymoGenetics Drug Advances to Clinical Trial
- DOBI Medical International Progresses With ComfortScan(R) PMA Clinical Trial
- DOBI Medical International Progresses With ComfortScan(TM) Clinical Trial
 |
 |
User Comments (0)
RSS Feeds